Relationship between the Acid-Inhibitory Effects of Two Proton Pump Inhibitors and CYP2C19 Genotype in Japanese Subjects: A Randomized Two-Way Crossover Study

• Published in: Journal of international medical research 2010-08, Vol.38 (4), p.1473-1483
• Main Authors: Furuta, K, Adachi, K, Ohara, S, Morita, T, Tanimura, T, Koshino, K, Kinoshita, Y
• Format: Article
• Language: English
• Subjects: 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage; 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology; Adult; Aryl Hydrocarbon Hydroxylases - genetics; Asian Continental Ancestry Group - genetics; Cross-Over Studies; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter pylori - drug effects; Helicobacter pylori - physiology; Humans; Hydrogen-Ion Concentration - drug effects; Japan; Male; Omeprazole - administration & dosage; Omeprazole - pharmacology; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacology; Rabeprazole; Young Adult
• ISSN: 0300-0605; 1473-2300
• DOI: 10.1177/147323001003800430

This two-way crossover study investigated possible differences between the proton pump inhibitors, omeprazole and rabeprazole, in their effect on gastric acid secretion in Japanese subjects with differing cytochrome P450, family 2, subfamily C, polypeptide 19 (CYP2C19) genotypes. A total of 23 Helicobacter pylori-negative healthy volunteers received omeprazole 20 mg/day and rabeprazole 10 mg/day. Each drug treatment was given for a continuous 7-day period allocated in random order, with an interval of at least 1 week between drug treatment periods to allow for wash-out. Intragastric pH was measured on days 1 and 7. Overall median intragastric pH levels at 7 and 8 h after the first administration were significantly higher with omeprazole. There was no significant difference in intragastric pH in homozygous extensive metabolizers, whereas intragastric pH was significantly higher with omeprazole in combined data from heterozygous extensive metabolizers and poor metabolizers at 6, 7 and 8 h after the first drug administration. There were no significant differences in intragastric pH between omeprazole and rabeprazole irrespective of genotype on day 7 of administration. In conclusion, on day 1 the time to onset of the antisecretory action of 20 mg/day omeprazole was more rapid than that of 10 mg/day rabeprazole in Japanese individuals who have a higher incidence of the CYP2C19 poor metabolizer genotype, however by day 7 no difference in antisecretory effect was found, regardless of genotype.